Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Fulcrum Therapeutics, Inc.”

8 pharma patents match "Fulcrum Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 8
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 8 pharmaceutical patents matching "Fulcrum Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

8 results for “Fulcrum Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12109198

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Fulcrum Therapeutics, Inc. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  2. US 11819554

    Compositions and methods for modulating FMR1 expression

    Fulcrum Therapeutics, Inc. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  3. US 11590111

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Fulcrum Therapeutics, Inc. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  4. US 11479770

    Use of p38 inhibitors to reduce expression of DUX4

    Fulcrum Therapeutics, Inc. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  5. US 11291659

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  6. US 10973805

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Fulcrum Therapeutics, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  7. US 10537560

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  8. US 10342786

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted